Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 2/20 | 0.38 |
| ▸ | ALPL | P05186 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 10/20 | 0.37 |
| ▸ | PGR | P06401 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | ESRRB | O95718 | 3/20 | 0.33 |
| ▸ | ESRRA | P11474 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4817120 | 0.75 | THRB (0.39) | THRBALPLKDM4EALDH1A1HSD17B10 | |
| SCHEMBL4814353 | 0.74 | THRB (0.46) | THRBALPLKDM4EALDH1A1HSD17B10 | |
| SCHEMBL4813066 | 0.73 | ALDH1A1 (0.50) | THRBALPLKDM4EALDH1A1HSD17B10 | |
| SCHEMBL6016756 | 0.71 | ALPL (0.38) | THRBALPLKDM4EALDH1A1HSD17B10 | |
| SCHEMBL11427034 | 0.68 | ALPL (0.36) | THRBALPLKDM4EALDH1A1HSD17B10 | |
| SCHEMBL4811094 | 0.67 | KDM4E (0.48) | THRBALPLKDM4EALDH1A1HSD17B10 | |
| SCHEMBL8811340 | 0.66 | PGR (0.41) | THRBALPLKDM4EALDH1A1HSD17B10 | |
| SCHEMBL11605734 | 0.65 | MAOB (0.41) | ALPLKDM4EALDH1A1HSD17B10MAPT | |
| SCHEMBL14440820 | 0.63 | POLB (0.34) | — | |
| SCHEMBL10176736 | 0.63 | ALPL (0.61) | THRBALPLKDM4EALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080293757-A1 | ABCA1 ELEVATING COMPOUNDS | ABELMAN MATTHEW | 2008-11-27 | — | — | US | disclosed |
| US-7432276-B2 | ABCA1 elevating compounds | CV THERAPEUTICS, INC. (US) | 2008-10-07 | — | — | US | disclosed |
| US-7423045-B2 | ABCA1 elevating compounds | CV THERAPEUTICS, INC. (US) | 2008-09-09 | — | — | US | disclosed |
| US-20070191379-A1 | ABCA1 elevating compounds | CV THERAPEUTICS, INC. | 2007-08-16 | — | — | US | disclosed |
| US-20070010544-A1 | ABCA1 elevating compounds | CV THERAPEUTICS, INC. | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191379-A1 | ABCA1 elevating compounds | ABCD3, ABCB4, CETP | THRB 1487/4885ALPL 3464/4885KDM4E 4502/4885 |
| US-20080293757-A1 | ABCA1 ELEVATING COMPOUNDS | ABCD3, ABCB4, CETP | THRB 1487/4885ALPL 3464/4885KDM4E 4502/4885 |
| US-20070010544-A1 | ABCA1 elevating compounds | ABCD3, ABCB4, CETP | THRB 1487/4885ALPL 3464/4885KDM4E 4502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.